Lanxess reported some moderate impact on profitability after the strong portfolio rotation. Rightly, the company became a stronger player in the specialities chemicals arena, which gives Lanxess’ EBITDA a certain robustness as it should be clear that margins are not carved in stone.
Lanxess reported a good set of figures, strongly beating our top-line expectations (+6.1%) and EBITDA was well ahead. Consensus was partly beaten (top line: +3.2%; adjusted EBTDA: 0%).
Current tensions prevented ....
14 Mar 2022
A decent 2021, but uncertainties hover over 2022
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A decent 2021, but uncertainties hover over 2022
Lanxess reported some moderate impact on profitability after the strong portfolio rotation. Rightly, the company became a stronger player in the specialities chemicals arena, which gives Lanxess’ EBITDA a certain robustness as it should be clear that margins are not carved in stone.
Lanxess reported a good set of figures, strongly beating our top-line expectations (+6.1%) and EBITDA was well ahead. Consensus was partly beaten (top line: +3.2%; adjusted EBTDA: 0%).
Current tensions prevented ....